Compare RGP & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGP | OKYO |
|---|---|---|
| Founded | 1996 | 2007 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.7M | 78.2M |
| IPO Year | 2000 | 2021 |
| Metric | RGP | OKYO |
|---|---|---|
| Price | $2.71 | $1.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $6.50 | ★ $8.33 |
| AVG Volume (30 Days) | ★ 473.9K | 43.7K |
| Earning Date | 10-07-2026 | 07-20-2026 |
| Dividend Yield | ★ 9.86% | N/A |
| EPS Growth | ★ 79.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $452,006,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.33 | $1.26 |
| 52 Week High | $5.37 | $3.20 |
| Indicator | RGP | OKYO |
|---|---|---|
| Relative Strength Index (RSI) | 37.22 | 49.10 |
| Support Level | $2.33 | $1.31 |
| Resistance Level | $3.86 | $1.71 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 73.15 | 21.44 |
Resources Connection Inc is a professional services firm. Its segments include On-Demand Talent provides businesses with a go-to source for bringing in experts when its needed, serving the office of the CFO; Consulting drives transformation across people, processes and technology across domain areas including finance, technology and digital, risk and compliance and operational performance; Europe & Asia Pacific offers both on-demand and consulting services to clients throughout Europe and Asia Pacific; Outsourced Services; and Sitrick. It derives the majority of revenue from On-Demand Talent segment. Geographically, it operates in United States and internationally.
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.